GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Price-to-Tangible-Book

CHMMF (Chimeric Therapeutics) Price-to-Tangible-Book : (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Price-to-Tangible-Book?

As of today (2024-12-11), Chimeric Therapeutics's share price is $0.001. Chimeric Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.00. Hence, Chimeric Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Chimeric Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 4 years, Chimeric Therapeutics's highest Price to Tangible Book Ratio was 8.47. The lowest was 3.29. And the median was 5.88.

CHMMF's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.9
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Chimeric Therapeutics's share price is $0.001. Chimeric Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.01. Hence, Chimeric Therapeutics's P/B Ratio of today is 0.08.

Chimeric Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Chimeric Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Price-to-Tangible-Book Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Price-to-Tangible-Book
- - - -

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Tangible-Book Get a 7-Day Free Trial - 15.00 - 30.00 -

Competitive Comparison of Chimeric Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Chimeric Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Price-to-Tangible-Book falls into.


Chimeric Therapeutics Price-to-Tangible-Book Calculation

Chimeric Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=0.001/0.001
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Chimeric Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Price-to-Tangible-Book
Comparable Companies
ASX:TRP ASX:VBS ASX:IMC ASX:PAB ASX:ATX ASX:KZA ASX:ATH ASX:IXC ASX:BGT ASX:ACR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CHM:Australia
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.chimerictherapeutics.com
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd at NWR Communications Virtual Conference Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research • 02-13-2024